Brief: Cantargia And GEICAM Present Nadunolimab Updated Phase 1 Clinical Data

Cantargia AB

12/12/2024 07:48

Dec 12 (Reuters) - Cantargia AB  CANTA.ST :
    * SAID ON WEDNESDAY CO AND GEICAM PRESENT UPDATED PHASE 1
CLINICAL
DATA AND NEW TRANSLATIONAL RESULTS ON NADUNOLIMAB TREATMENT IN
ADVANCED TRIPLE NEGATIVE BREAST CANCER
    * UPDATED RESULTS CONFIRM AN ACCEPTABLE SAFETY PROFILE WITH
A
PROMISING EFFICACY OF 60% RESPONSE RATE, 6.2 MONTHS
PROGRESSION-FREE SURVIVAL (PFS), AND 12.8 MONTHS OVERALL
SURVIVAL (OS)

        
 Source text for Workspace:  ID:nNDL3s2NW7 
 Further company coverage:  CANTA.ST  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))